|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS12290 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-SRPK2 |
| 克隆性 | 是 |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human SRPK2 |
產(chǎn)品訂購信息：
英文名稱 Anti-SRPK2
中文名稱 絲氨酸/蘇氨酸蛋白激酶SRPK2抗體規(guī)格
別 名 Human serine kinase SRPK2 mRNA, complete cds; Serine kinase SRPK2; Serine/arginine rich protein specific kinase 2; Serine/threonine protein kinase SRPK2; SFRS protein kinase 2; SFRSK2; SR protein specific kinase 2; SRPK2_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 信號轉(zhuǎn)導(dǎo) 細(xì)胞周期蛋白 激酶和磷酸酶 表觀遺傳學(xué)
蛋白分子量 predicted molecular weight: 77kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SRPK2
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
絲氨酸/蘇氨酸蛋白激酶SRPK2抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 SRPK2 belongs to the protein kinase superfamily. It phosphorylates RS domain-containing proteins, such as SFRS1 and SFRS2 on serine residues. It has a role in spliceosome assembly and in mediating the trafficking of splicing factors and appears to mediate HBV core protein phosphorylation which is a prerequisite for pregenomic RNA encapsidation into viral capsids. SRPK2 highly expressed in brain, moderately expressed in heart and skeletal muscle and at low levels in lung, liver, and kidney.
Function : Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing. Promotes neuronal apoptosis by up-regulating cyclin-D1 (CCND1) expression. This is done by the phosphorylation of SRSF2, leading to the suppression of p53/TP53 phosphorylation thereby relieving the repressive effect of p53/TP53 on cyclin-D1 (CCND1) expression. Phosphorylates ACIN1, and redistributes it from the nuclear speckles to the nucleoplasm, resulting in cyclin A1 but not cyclin A2 up-regulation. Plays an essential role in splicesomal B complex formation via the phosphorylation of DDX23/PRP28. Can mediate hepatitis B virus (HBV) core protein phosphorylation. Plays a negative role in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein but by reducing the packaging efficiency of the pregenomic RNA (pgRNA) without affecting the formation of the viral core particles.
Subunit : Interacts with PKB/AKT1 in a phosphorylation-dependent manner. The phosphorylated form (by PKB/AKT1) interacts with YWHAB and YWHAE. Interaction with YWHAB suppresses its cleavage by caspases and inhibits the release of its N-terminal pro-apoptotic fragment. Interacts with SFN. Associates with U4/U6-U5 tri-small nuclear ribonucleoproteins (U4/U6-U5 tri-snRNPs).
Subcellular Location : Cytoplasm. Nucleus. Note=Shuttles between the nucleus and the cytoplasm. KAT5/TIP60 inhibits its nuclear translocation. Phosphorylation at Thr-492 by PKB/AKT1 promotes nuclear translocation.
Tissue Specificity : Highly expressed in brain, moderately expressed in heart and skeletal muscle and at low levels in lung, liver, and kidney.
Post-translational modifications : Proteolytically cleaved at Asp-139 and Asp-403 by caspase-3 during apoptotic cell death. Cleavage at Asp-139 which is the major site of cleavage, produces a small N-terminal fragment that translocates into nucleus and promotes VP16-induced apoptosis.
Similarity : Phosphorylation at Thr-492 by PKB/AKT1 enhances its stimulatory activity in triggering cyclin-D1 (CCND1) expression and promoting apoptosis in neurons, which can be blocked by YWHAB. It also enhances its protein kinase activity toward ACIN1 and SRSF2, promotes its nuclear translocation and prevents its proteolytic cleavage.
Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family.
Contains 1 protein kinase domain.
Database links : UniProtKB/Swiss-Prot: P78362.3
緊密連接蛋白3 多克隆抗體 ZO3 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
絲氨酸蛋白酶抑制劑A10 多克隆抗體 ZPI Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
鋅指蛋白206 多克隆抗體 ZSC10 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
鋅指蛋白854 多克隆抗體 ZSCA2 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
B-2 單克隆抗體 Bcl-2 Monoclonal Antibody 700/30ul#1540/100ul#2520/200ul
萊姆病螺旋體抗體 有絲分裂相關(guān)蛋白INSC抗體
成熟相關(guān)蛋白BOULE抗體 有絲分裂細(xì)胞周期蛋白MPP9抗體
伸長因子結(jié)合蛋白抗體 有絲分裂驅(qū)動蛋白樣2抗體
特異性堿性蛋白Y2抗體 有絲分裂驅(qū)動蛋白樣2B抗體
易感基因2相關(guān)蛋白抗體 有絲分裂驅(qū)動蛋白樣1抗體
鋅指蛋白20D3抗體 24脫氫膽固醇還原酶抗體
鋅指蛋白804A抗體 22號染色體開放閱讀框9抗體
負(fù)調(diào)控因子白細(xì)胞介素2抗體 22號染色體開放閱讀框45抗體
鋅指蛋白BED3抗體 22號染色體開放閱讀框43抗體
鋅指蛋白379抗體 22號染色體開放閱讀框40抗體
羽葉白頭樹Garuga pinnata Reynorin 槲皮素-3-D-木糖甙 549-32-6 C20H18O11 ≥95%
蟾毒靈BufclinHPLC≥98%，20mg/支
(R型)人參皂苷Rg3 20(R)Ginsenoside Rg3 20mg HPLC≥98% 用于含量測定
中藥對照藥材地耳草121468-200401TLC法鑒別
Sweroside獐芽菜苷純度：98%
絲氨酸/蘇氨酸蛋白激酶SRPK2抗體規(guī)格光葉巴豆Croton laevigatus Taraxerone 蒲公英賽酮 514-07-8 C30H48O ≥98.5%
遠(yuǎn)華蟾蜍精Tqlocinobufcgin1947-6-420mg
蓮心減 Liensinine 2586-96-1 20mg HPLC≥98% 用于含量測定
含量測定醋谷胺100859-200501常溫，避光100mg
5-去甲川陳皮素 5-Demetxylnobiletin 2174-59-6 20mg HPLC≥98% 5-去甲川陳皮素 2174-59-6
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 絲氨酸/蘇氨酸蛋白激酶SRPK2抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時,或位于酶的催化位點(diǎn)時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）絲氨酸/蘇氨酸蛋白激酶SRPK2抗體規(guī)格 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
